Prospect Therapeutics’ In Vitro Studies Demonstrate that GCS-100 Drug Binds to and Blocks the Effects of Galectin-3
- Induction of apoptosis
- Inhibition of angiogenesis
- Inhibition of cancer cell proliferation
- Inhibition of metastasis
The intellectual property, regulatory dossier, fixed assets and clinical inventory of Prospect will be sold at auction on
Persons interested in bidding must sign a Confidentiality Agreement (“CA”) obtained from Finn’s Office – email@example.com or 781-237-8840. They will then receive a bid package.
About Prospect Therapeutics, Inc.
Prospect’s lead product candidate, GCS-100, is a carbohydrate molecule designed to inhibit the activity of galectin-3, a protein found in high concentration in a broad range of human cancers and whose over-expression is associated with poor prognosis in cancer patients.